NAECB Allergy & Asthma 4

Question 1

A child with asthma has an FEV1 of 65% predicted on spirometry during a flare. According to NAEPP, this exacerbation severity is classified as:

Accepted Answer

Moderate

Answer

An FEV1 of 40–69% predicted indicates a moderate asthma exacerbation according to NAEPP guidelines.

Question 2

Which environmental control measure has the strongest evidence for reducing house dust mite allergen exposure?

Accepted Answer

Allergen-impermeable mattress and pillow covers

Answer

Allergen-impermeable encasements for mattresses and pillows have the strongest evidence for reducing dust mite allergen concentrations in bedding.

Question 3

Which finding on methacholine challenge testing is considered a positive result indicating bronchial hyperresponsiveness?

Accepted Answer

≥20% fall in FEV1 at ≤16 mg/mL (PC20 ≤16 mg/mL)

Answer

A PC20 of ≤16 mg/mL (≥20% fall in FEV1 at ≤16 mg/mL methacholine) is considered a positive methacholine challenge indicating bronchial hyperresponsiveness.

Question 4

A patient on subcutaneous allergen immunotherapy (SCIT) develops generalized urticaria and hypotension 15 minutes post-injection. After epinephrine administration, what is the next critical step?

Accepted Answer

Observe for at least 4 hours for biphasic reaction

Answer

After treating anaphylaxis from SCIT, patients must be observed for at least 4 hours due to the risk of a biphasic anaphylactic reaction.

Question 5

Which biologic agent targets IL-5 to reduce eosinophil counts and is approved for severe eosinophilic asthma?

Accepted Answer

Mepolizumab

Answer

Mepolizumab is an anti-IL-5 monoclonal antibody that reduces eosinophil production and is approved for severe eosinophilic asthma.

NAECB Exam Practice Test

NAECB Exam Practice Test

NAECB Allergy & Asthma 4